<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238796</url>
  </required_header>
  <id_info>
    <org_study_id>9809-CL-1407</org_study_id>
    <nct_id>NCT01238796</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin</brief_title>
  <official_title>A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of renal function on the biological&#xD;
      activity of telavancin using blood samples obtained from subjects with normal renal function,&#xD;
      severe renal impairment, and end stage renal disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of telavancin as estimated by antibiotic potency bioassay</measure>
    <time_frame>Days 1-4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of telavancin as determined by standard Liquid Chromatography Tandem Mass Spectrometer (LC/MS/MS)</measure>
    <time_frame>Days 1-4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables through analysis of blood samples</measure>
    <time_frame>Days 1-4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End stage renal disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with end stage renal disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telavancin</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>End stage renal disease</arm_group_label>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <other_name>VIBATIV®</other_name>
    <other_name>TD-6424</other_name>
    <other_name>ASP9809</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Weighs at least 45 kg and body mass index of 18 to 40 kg/m2, inclusive&#xD;
&#xD;
          -  An estimated creatinine clearance value based on Cockcroft-Gault method of:&#xD;
&#xD;
               -  &gt;80 mL/min for subjects with normal renal function&#xD;
&#xD;
               -  &lt;30 mL/min for subjects with severe renal impairment&#xD;
&#xD;
               -  receiving hemodialysis three times a week for subjects with end stage renal&#xD;
                  impairment&#xD;
&#xD;
          -  If female, the subject is at least 2 years postmenopausal, surgically sterile or&#xD;
             practicing effective birth control, and is not pregnant or lactating&#xD;
&#xD;
          -  Good venous access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant acute illness (other than renal disease and&#xD;
             conditions related to the renal disease in renal impairment subjects, such as stable&#xD;
             diabetes or hypertension)&#xD;
&#xD;
          -  Has had a kidney transplant that is still functioning&#xD;
&#xD;
          -  History of unexplained syncope, cardiac arrest, unexplained cardiac arrythmia or&#xD;
             torsade de pointes, structural heart disease, prolonged QT interval, or family history&#xD;
             of long QT syndrome&#xD;
&#xD;
          -  Known hypersensitivity to telavancin or any of the excipients in the formulation, or a&#xD;
             history of severe allergic or anaphylactic reactions&#xD;
&#xD;
          -  History of consuming more than 7 units of alcoholic beverages per week, or history of&#xD;
             alcoholism or substance abuse within past 2 years&#xD;
&#xD;
          -  Known to be positive for human immunodeficiency virus antibody&#xD;
&#xD;
          -  For subjects with normal renal function, has had treatment with prescription or&#xD;
             non-prescription drugs, including complementary and alternative medicines or over-the&#xD;
             counter medications, with the exception of oral contraceptives, hormone replacement&#xD;
             therapy, daily aspirin, and occasional use of acetaminophen within the past 14 days&#xD;
&#xD;
          -  For subjects with renal impairment, has not been on a stable dose of concomitant&#xD;
             medications for at least 2 weeks prior to study start or is taking any medication that&#xD;
             would interfere with the evaluation of televancin in this study&#xD;
&#xD;
          -  Has received an experimental agent within 30 days or ten half-lives, whichever is&#xD;
             longer, prior to study drug administration&#xD;
&#xD;
          -  Has had any significant blood loss, donated one unit (450 mL) of blood or more, or&#xD;
             received a transfusion of any blood or blood products within 60 days or donated plasma&#xD;
             within 7 days prior to admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Cumberland Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>telavancin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Severe renal disease</keyword>
  <keyword>VIBATIV®</keyword>
  <keyword>ASP9809</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telavancin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

